The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

It’s clear there’s a strong connection between sustained earnings growth and hall-of-fame returns. On that note, here are three market-beating stocks that could turbocharge your returns.

AutoZone (AZO)

Five-Year Return: +235%

Aiming to be a one-stop shop for the DIY customer, AutoZone (NYSE: AZO) is an auto parts and accessories retailer that sells everything from car batteries to windshield wiper fluid to brake pads.

Why Are We Bullish on AZO?

1. Same-store sales growth lends it the confidence to gradually expand its store base so it can reach more customers
2. Disciplined cost controls and effective management resulted in a strong two-year operating margin of 19.6%
3. Industry-leading 40.4% return on capital demonstrates management’s skill in finding high-return investments

At $3,752 per share, AutoZone trades at 24.5x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.

Primoris (PRIM)

Five-Year Return: +415%

Listed on the NASDAQ in 2008, Primoris (NYSE: PRIM) builds, maintains, and upgrades infrastructure in the utility, energy, and civil construction industries.

Why Are We Backing PRIM?

1. Sales pipeline is in good shape as its backlog averaged 143% growth over the past two years
2. Earnings per share have massively outperformed its peers over the last two years, increasing by 39.1% annually
3. Free cash flow margin increased by 5.9 percentage points over the last five years, giving the company more capital to invest or return to shareholders

Primoris’s stock price of $149.95 implies a valuation ratio of 27.7x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.

Boston Scientific (BSX)

Five-Year Return: +164%

Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.

Why Are We Positive On BSX?

1. Average organic revenue growth of 16.2% over the past two years demonstrates its ability to expand independently without relying on acquisitions
2. Additional sales over the last five years increased its profitability as the 19.9% annual growth in its earnings per share outpaced its revenue
3. Free cash flow margin expanded by 5.5 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends

Boston Scientific is trading at $93.50 per share, or 28.2x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.

Stocks We Like Even More

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.